Leqembi (lecanemab-irmb) - Biogen, Eisai
Longitudinal patterns of regional cerebral blood flow during anti-amyloid therapy in mild cognitive impairment: a pilot ASL MRI case series. (PubMed, Front Aging Neurosci) - Oct 1, 2026 - "This pilot observational case series included participants with MCI or very early Alzheimer's disease undergoing anti-amyloid therapy (lecanemab), who underwent longitudinal pseudo-continuous ASL MRI at baseline and predefined follow-up timepoints...The observed rCBF trajectories demonstrate region-specific and time-dependent perfusion changes over the treatment period. Given the small sample size, absence of longitudinal imaging in the control group, and residual vascular confounding, these findings should be interpreted cautiously as exploratory and hypothesis-generating rather than evidence of treatment efficacy." 
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders
http://www.ncbi.nlm.nih.gov/pubmed/42812519
 
Eva Y W Cheung; Henry K F Mak; Hui Zhang; Ka Keung Yam; Koon Ho Chan; Kyongtae T Bae; Patrick K C Chiu; Yat Fung Shea
 
Oct 1, 2026
 
Prev Next